Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Century Therapeutics, Inc. (NASDAQ: IPSC) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including Forms 10-K, 10-Q, 8-K and other submissions. These filings offer detailed information on Century Therapeutics’ iPSC-derived cell therapy pipeline, financial position and material corporate events.
Century Therapeutics uses its SEC reports to describe its focus on autoimmune diseases, cancer and Type 1 diabetes, its Allo-Evasion™ immune evasion technology, and programs such as CNTY-101, CNTY-308 and CNTY-813. Current reports on Form 8-K have disclosed items like private placement financing arrangements, Nasdaq listing status developments, workforce reductions, board and executive changes, and earnings press releases.
Through periodic filings such as Forms 10-Q and 10-K, investors can review Century Therapeutics’ reported cash, cash equivalents and investments, research and development and general and administrative expenses, collaboration revenue recognition and accumulated deficit. Risk factor and business sections in these reports provide the company’s own discussion of uncertainties related to clinical development, regulatory approvals, collaborations and market conditions.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of new documents. Real-time updates from EDGAR ensure that new IPSC filings, including 8-Ks on material events and any Form 4 insider transaction reports, are added as they become available. Use this page to navigate directly to the filings most relevant to your analysis of Century Therapeutics’ business, pipeline and capital structure.
Century Therapeutics, Inc. (IPSC) President and CEO insider purchase was reported on a Form 4. The reporting person, who is also a director, bought 35,000 shares of Century Therapeutics common stock on 11/19/2025 at a weighted average price of $0.4951 per share. Following this open-market purchase, the insider beneficially owns 3,271,453 shares, held directly. The filing notes that all profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements, and the price reflects multiple trades between $0.488 and $0.5005 per share.
Century Therapeutics, Inc. (IPSC) reported an insider transaction by its President and CEO, who is also a director of the company. On 11/17/2025, the reporting person sold 32,456 shares of common stock at a price of $0.454 per share.
According to the explanation provided, these sales represent shares sold to cover tax withholding obligations arising from the vesting of restricted stock units and were described as automatic, not at the discretion of the reporting person. After this transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.
Century Therapeutics, Inc. (IPSC) furnished materials related to its latest quarter and pipeline. The company provided an earnings press release for the quarter ended September 30, 2025, and an updated investor presentation. It also announced its first Type 1 diabetes program, CNTY-813.
The earnings release (Exhibit 99.1), investor presentation (Exhibit 99.2), and CNTY-813 press release (Exhibit 99.3) were furnished on November 13, 2025 and are not deemed “filed” under the Exchange Act.
Century Therapeutics (IPSC) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $34,422$9,591, driven by $109,164 of collaboration revenue recognized in Q1 when option rights expired.
Total assets were $244,717 versus $353,216 at year‑end, reflecting lower investments and lease assets. Cash, cash equivalents and investments were $132,748 as of September 30, 2025. Current liabilities declined to $22,026 from $129,782, primarily as deferred revenue was recognized. Stockholders’ equity rose to $176,348.
Q3 operating expenses were $36,124, including R&D $22,526, G&A $6,835, and a $6,763 impairment tied to lease strategy changes. The company executed lease modifications, recording a $1,395 gain and expects Seattle and Boston lease terminations by early 2026 with a new Watertown lease to commence thereafter. Management states it has adequate resources to operate for at least the next 12 months. As of November 1, 2025, common shares outstanding were 87,307,091.
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
Century Therapeutics insider filing reports a grant of restricted stock units to the company’s Chief Scientific Officer. The report shows 762,543 RSUs were granted on 09/18/2025; each RSU represents a contingent right to one share of common stock and will be settled in shares on each vesting date. The RSUs vest 50% on October 1, 2026 and the remaining 50% on October 1, 2027, subject to continued service. After the grant the reporting person beneficially owns 992,489 shares directly and 10,697 shares indirectly via the Cowan Investment Nominee Trust, which the filer disclaims except for any pecuniary interest.
Douglas Carr, SVP Finance & Operations reported a small, automated sale of company stock to cover tax withholding related to restricted stock unit vesting. On 09/08/2025 he disposed of 263 shares of Century Therapeutics, Inc. (IPSC) at $0.50 per share, leaving 405,423 shares beneficially owned in a direct capacity.
The Form 4 states the sales were automatic and not at the reporting person’s discretion, made solely to satisfy tax-withholding obligations. The filing is signed by the reporting person on 09/10/2025.
Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc. (IPSC), reported a small automatic sale of common stock on 09/08/2025 to satisfy tax withholding related to the vesting of restricted stock units. The Form 4 shows 488 shares were sold at $0.50 per share, and following the reported transaction the reporting person beneficially owns 3,268,909 shares, held directly. The filing states the sales were automatic to cover tax obligations and not at the reporting person’s discretion.
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (IPSC), reported transactions on Form 4 showing an automatic sale of 539 shares of common stock on 09/08/2025 at a price of $0.50 per share to satisfy tax withholding related to the vesting of restricted stock units. After the reported sale, Mr. Russotti is shown as directly owning 391,508 shares and indirectly owning 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing was signed by an attorney-in-fact on 09/10/2025. The Form 4 notes the sales were automatic and not made at the reporting person's discretion.
Century Therapeutics (IPSC) filed a Form 144 reporting a proposed sale of 488 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $243.95. The shares were acquired on 09/05/2025 as a restricted stock vesting event and payment is listed as compensation. The filer indicates the approximate date of sale as 09/08/2025 and cites NASDAQ as the exchange. The filing also discloses two sales by the same person in the past three months: 475 shares sold on 06/09/2025 for $295.50 and 30,745 shares sold on 08/18/2025 for $17,521.58. The notice includes the standard representation that the seller has no undisclosed material adverse information.